High-dose vitamin C supplementation in patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized, triple-blind, placebo-controlled trial.

Plasma vitamin C levels were significantly higher in the vitamin C group at all measured time points.

• Measurements were taken at days 0, +7, +15, and discharge
• Difference was statistically significant at all time points (P < 0.001)
• The intervention consisted of intravenous vitamin C at 50 mg/kg/day from day +1 to +14, followed by oral vitamin C 500 mg/day until day +100
• 31 adult allo-HSCT patients were randomized in this pilot triple-blind, placebo-controlled trial

A trend toward reduced acute graft-versus-host disease (aGVHD) was observed in the vitamin C group compared to placebo, though not statistically significant.

• aGVHD occurred in 33% of the vitamin C group versus 44% of the placebo group
• The difference did not reach statistical significance
• The trial was described as a pilot study with a small sample size of 31 patients

A trend toward lower oral mucositis severity and shorter duration was observed in the vitamin C group, though not statistically significant.

• Severe oral mucositis occurred in 46.6% of the vitamin C group versus 62.5% of the placebo group
• Mean mucositis duration was 7.5 ± 3.6 days in the vitamin C group versus 9.1 ± 3.7 days in the placebo group
• These differences did not reach statistical significance

No significant adverse events were reported with high-dose intravenous and subsequent oral vitamin C supplementation in allo-HSCT patients.

• Intravenous dose was 50 mg/kg/day administered from day +1 to +14
• Oral supplementation of 500 mg/day followed from day +15 until day +100
• Safety was monitored throughout the 100-day post-transplant period

The study was designed as a pilot randomized, triple-blind, placebo-controlled trial to evaluate early high-dose vitamin C supplementation in allo-HSCT patients.

• 31 adult patients undergoing allogeneic hematopoietic stem cell transplantation were enrolled
• Patients were randomized to intravenous vitamin C (50 mg/kg/day) or placebo from day +1 to +14
• Followed by oral vitamin C (500 mg/day) or placebo until day +100
• Patients were monitored for post-HSCT complications until day +100
• Allo-HSCT is described as a curative treatment for hematological disorders that often results in micronutrient deficiency and complications